As low as $330.00 a month
 
A recent study in *Nature Medicine* showed that Tirzepatide can help people lose over 60 pounds, which is at least a quarter of their body weight, especially when they also make lifestyle changes.
Semaglutide is an effective weight-loss medication, but it's not right for everyone. When sold as Ozempic®, it is for diabetes patients. When sold as Wegovy®, it is approved by the FDA for treating overweight and obesity. Tirzepatide is available as Mounjaro® for diabetes. In November 2023, it received FDA approval to treat obesity under the name Zepbound®.
**Effects of Tirzepatide on Metabolism and Heart Health**  
Tirzepatide has been shown to lower blood pressure (BP) in clinical studies. Patients who took Tirzepatide had significantly lower systolic and diastolic BP than those who did not take it. This was true whether Tirzepatide was used alone or with other treatments.
Low-grade inflammation can increase the risk of heart disease. Clinical trials show that Tirzepatide may improve inflammatory markers. For example, a 26-week phase 2 study with patients who have obesity and Type 2 Diabetes Mellitus (T2DM) showed these positive results.